Health Condition 1: B962- Escherichia coli [E. coli ] as thecause of diseases classified elsewhere Health Condition 2: B961- Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified elsewhere Health Condition 3: B965- Pseudomonas (aeruginosa) (mallei)(pseudomallei) as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Meropenem extended infusion: Meropenem given as infusion over 3 hours upto 7 days
Control Intervention1: Meropenem bolus: Meropenem given over 30 minutes upto 7 days
Sponsors
Armed Forces Medical College, Pune
Eligibility
Inclusion criteria
Inclusion criteria: Patients with culture reports suggesting Gram Negative Bacteremia susceptible to Meropenem. Patients initiated on Meropenem therapy by the treating Physician. SOFA score 2 12
Exclusion criteria
Exclusion criteria: Pregnancy and lactation. Known allergies to Penicillin. Patients on any other antibiotic with similar spectrum as that of Meropenem
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the rate of complete resolution of leukocytosis (TLC less than 11,000/cumm) and rate of being afebrile (Temp below 99F for 24hrs) in patients with culture positive gram-negative bacteremia being treated with meropenem given as extended infusion versus intermittent dosingTimepoint: at the end of 07 days | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the time (in days) taken for clinical cure in both groupsTimepoint: ;To compare the mean change in SOFA scores in both groupsTimepoint: at the end of 7 days after the start of meropenem therapy;To compare the mean duration of hospital stay among both groups of patientsTimepoint: ;To compare the all-cause mortality rateTimepoint: at the end of 30 days | — |
Countries
India
Contacts
Public ContactSiva Bhanu Prakash Prudhivi
Armed Forces Medical College, Pune
Outcome results
None listed